Summary & Overview
HCPCS Level II J0870: Imetelstat Injection, 1 mg
HCPCS Level II code J0870 denotes imetelstat billed per 1 mg for injection/infusion. This code identifies administration of a specialized oncologic agent and is relevant for facility billing, prior authorization workflows, and specialty pharmacy coordination. Nationally, high-cost injectable cancer therapies carrying unique J-codes are focal points for coverage policy, utilization management, and payer-provider contracting.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the payer landscape addressed. The publication outlines benchmarks for coverage and reimbursement practices, common billing considerations tied to single-dose unit reporting, and policy updates that affect prior authorization and medical necessity determinations.
The content provides clinical context for imetelstat use as an injectable oncology treatment, operational implications for infusion centers, and billing details relevant to claims submission and audit readiness. Data not available in the input are noted where applicable. This summary serves as a national reference for revenue cycle, clinical operations, and payer relations teams handling specialty oncology drug claims.
Billing Code Overview
HCPCS Level II code J0870 represents an injectable oncology agent: imeltalstat, billed per 1 mg unit. The service type is injection/infusion drug administration, typically delivered in an outpatient infusion center or hospital outpatient department. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J0870 (imetelstat, 1 mg) is an adult with a myeloid malignancy such as myelodysplastic syndromes (MDS) or myeloproliferative neoplasm (MPN) who requires parenteral, weight- or dose-based cytotoxic therapy administered in an outpatient oncology clinic or infusion center. The clinical workflow begins with a hematology/oncology evaluation documenting diagnosis, prior therapies, performance status, baseline labs (CBC with differential, comprehensive metabolic panel, liver function tests), and informed consent for chemotherapy. On day of treatment, the patient undergoes pre-infusion assessment (vital signs, review of labs for cytopenias and hepatic function), intravenous access placement (peripheral IV or central line), and administration of pre-medications if indicated (antiemetic or supportive agents per institutional protocol). Pharmacy verifies the J0870 dose and prepares the medication under sterile compounding conditions. Nursing performs infusion and monitors for acute infusion reactions, cytopenias, or other adverse events. Post-infusion monitoring includes vital signs, documentation of any immediate reactions, and scheduling of follow-up labs and hematology visits to assess response and toxicity. Typical sites of service are outpatient hospital infusion centers, physician office infusion suites, and specialized oncology clinics. Inpatient administration may occur for severe complications or when admission is required for concurrent care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|